NCT05026866进行中（未招募）3 期
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 2,996
- 试验地点
- 213
- 主要终点
- Time to Clinical Progression of Composite Endpoint as Measured by Clinical Dementia Rating (CDR) in the Primary Study Population (Baseline CDR-Global Score [GS 0])
研究概览
简要总结
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD) over up to 332 weeks. Approximately 800 additional participants will be enrolled in the 12-month Addendum 7 to assess safety of a different titration regimen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 55 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A Telephone Interview for Cognitive Status - modified (TICS-M) score reflective of intact cognitive functioning.
- •Has a phosphorylated tau (P-tau) result consistent with the presence of amyloid pathology.
- •Has a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.
- •Have adequate literacy, vision, and hearing for neuropsychological testing at screening.
- •Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
- •Female participants include those who are infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as Mullerian agenesis; or post menopausal (women 55 or older not on hormone therapy and had at least 12 months of spontaneous amenorrhea; or with a diagnosis of menopause prior to starting hormone replacement therapy.
- •Treatment Extension: (Study Period II Placebo Group Only)
- •Are actively participating in Study AACM at the conclusion of Study Period III.
排除标准
- •Mild cognitive impairment or dementia, or significant other neurodegenerative disease that can affect cognition.
- •Current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease that could interfere with the analysis of the study or a life expectancy of approximately ≤5 years.
- •History of cancer with high risk of recurrence and preventing completion of the trial.
- •History of clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions (including but not limited to erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, and/or exfoliative dermatitis).
- •Have any clinically important abnormality at screening on magnetic resonance imaging (MRI) or clinical laboratory test results that could be detrimental to the participant or study integrity.
- •Have any contraindications for MRI, including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker.
- •Have a centrally read MRI demonstrating presence of amyloid-related imaging abnormalities (ARIA-E), >4 cerebral microhemorrhages, more than 1 area of superficial siderosis, any macrohemorrhage or severe white matter disease at screening.
- •Have had prior treatment with a passive anti-amyloid immunotherapy <5 half-lives prior to randomization.
- •Have received active immunization against amyloid beta (Aβ) in any other study.
- •Have received active immunization against Aβ in any other study.
- •Current or previous use of prescription medications used as treatment for mild cognitive impairment (MCI) or AD.
- •Addendum 7 Exclusion Criteria:
- •Same as the main study except contraindications for florbetapir F 18 PET are exclusionary.
研究组 & 干预措施
Donanemab
Experimental
Donanemab administered intravenously (IV)
干预措施: Donanemab (Drug)
Placebo
Placebo Comparator
Placebo is administered intravenously
干预措施: Placebo (Drug)
结局指标
主要结局
Time to Clinical Progression of Composite Endpoint as Measured by Clinical Dementia Rating (CDR) in the Primary Study Population (Baseline CDR-Global Score [GS 0])
时间窗: Estimated up to Week 332
Time to clinical progression as measured by CDR. CDR is a clinician-rated scale that provides an overall assessment of the participant's stage on the spectrum of Alzheimer's Disease (AD) dementia
次要结局
- Change from Baseline in Cognitive Composite in the Primary Study Population (Baseline CDR-GS 0)(Baseline, Up to Week 332)
- Change from Baseline in International Shopping List Test (ISLT) in the Primary Study Population (Baseline CDR-GS 0)(Baseline, Up to Week 332)
- Change from Baseline in Continuous Paired Associate Learning (CPAL ) in the Primary Study Population (Baseline CDR-GS 0)(Baseline, Up to Week 332)
- Change from Baseline in International Daily Symbol Substitution Test-Medicines (iDSSTm) in the Primary Study Population (Baseline CDR-GS 0)(Baseline, Up to Week 332)
- Change from Baseline in Category Fluency in the Primary Study Population (Baseline CDR-GS 0)(Baseline, Up to Week 332)
- Change from Baseline in CDR-Sum of Boxes (CDR-SB) n the Primary Study Population (Baseline CDR-GS 0)(Baseline, Up Week 332)
- Change from Baseline in Cognitive Function Index (CFI) in the Primary Study Population (Baseline CDR-GS 0)(Baseline, Up to Week 332)
- Change from Baseline in Montreal Cognitive Assessment (MoCA) Score in the Primary Study Population (Baseline CDR-GS 0)(Baseline, Up to Week 332)
- Change from Baseline in Mild Behavioral Impairment Checklist (MBI-C) in the Primary Study Population (Baseline CDR-GS 0)(Baseline, Up to Week 332)
- Time to Clinical Progression of Composite Endpoint as Measured by CDR in the Overall Study Population (Baseline CDR-GS 0 or 0.5)(Baseline, Up to Week 332)
- Time to Clinical Progression as Measured by CDR Memory Box in Primary Study Population (Baseline CDR-GS 0)(Estimated up to Week 332)
- Time to Clinical Progression as Measured by CDR Judgment and Problem Solving Box in the Primary Study Population (Baseline CDR-GS 0)(Estimated up to Week 332)
- Time to Clinical Progression as Measured by At Least 0.5 Change on CDR-SB in Primary Study Population (Baseline CDR-GS 0)(Estimated up to Week 332)
- Time to Clinical Progression of Composite Endpoint as Measured by CDR in Subpopulation Positive Based on Secondary Diagnostic Test(Estimated up to Week 332)
- Change from Baseline in Plasma P-tau217(Baseline, Up to Week 332)
- Pharmacokinetics (PK): Average Serum Donanemab Concentration at Steady State(Baseline through Week 76)
- Percentage of Participants with Treatment-emergent Anti-Drug Antibody (ADAs)(Baseline through Week 16)
研究者
研究点 (213)
Loading locations...
相似试验
进行中（未招募）
3 期
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)JPRN-jRCT2031220335Masaki Takeshi3,300
已完成
2 期
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)Alzheimer DiseaseBrain DiseasesCentral Nervous System DiseasesCognitive ImpairmentDementiaNCT04640077Eli Lilly and Company95
进行中（未招募）
3 期
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)Alzheimer DiseaseNCT04437511Eli Lilly and Company1,736
已完成
1 期
A Study of Donanemab (LY3002813) in Healthy Chinese ParticipantsHealthyNCT05533411Eli Lilly and Company36
进行中（未招募）
3 期
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)Alzheimer DiseaseBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental DisordersDementiaNCT05508789Eli Lilly and Company1,500